Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered as Single Bolus Injections in Subjects With Stage 5 Chronic Kidney Disease on Dialysis Therapy (CKD-5D)

• Status: Completed
• Trial end date: 2012-11-01

Summary

The purpose of this study is to assess Pharmakokinetic properties of iron isomaltoside 1000 (Monofer®) in doses of 100 mg, 200 mg or 500 mg in subjects with Stage 5 Chronic Kidney Disease on Dialysis Therapy (CKD-5D).

• Phase: Phase 1

Details

• Lead Sponsor: Pharmacosmos A/S
• Collaborator: ClinSmart
• Treatments: Ferric Compounds